The Influence of CYP2D6 Phenotype on the Pharmacokinetic Profile of Atomoxetine in Caucasian Healthy Subjects

Open access

Abstract

Objective: To analyze a potential phenotypic variation within the studied group based on the pharmacokinetic profile of atomoxetine and its active metabolite, and to further investigate the impact of CYP2D6 phenotype on atomoxetine pharmacokinetics. Methods: The study was conducted as an open-label, non-randomized clinical trial which included 43 Caucasian healthy volunteers. Each subject received a single oral dose of atomoxetine 25 mg. Subsequently, atomoxetine and 4-hydroxyatomoxetine-O-glucuronide (glucuronidated active metabolite) plasma concentrations were determined and a noncompartmental method was used to calculate the pharmacokinetic parameters of both compounds. Further on, the CYP2D6 metabolic phenotype was assessed using the area under the curve (AUC) metabolic ratio (atomoxetine/ 4-hydroxyatomoxetine-O-glucuronide) and specific statistical tests (Lilliefors (Kolgomorov-Smirnov) and Anderson-Darling test). The phenotypic differences in atomoxetine disposition were identified based on the pharmacokinetic profile of the parent drug and its metabolite. Results: The statistical analysis revealed that the AUC metabolic ratio data set did not follow a normal distribution. As a result, two different phenotypes were identified, respectively the poor metabolizer (PM) group which included 3 individuals and the extensive metabolizer (EM) group which comprised the remaining 40 subjects. Also, it was demonstrated that the metabolic phenotype significantly influenced atomoxetine pharmacokinetics, as PMs presented a 4.5-fold higher exposure to the parent drug and a 3.2-fold lower exposure to its metabolite in comparison to EMs. Conclusions: The pharmacokinetic and statistical analysis emphasized the existence of 2 metabolic phenotypes: EMs and PMs. Furthermore, it was proved that the interphenotype variability had a marked influence on atomoxetine pharmacokinetic profile.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Corman SL Fedutes BA Culley CM. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder. Am J Health Syst Pharm. 2004;61(22):2391-99.

  • 2. B Barton J. Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder. Arch Dis Child. 2005;90 Suppl 1:i26-9.

  • 3. Sauer J-M Ring BJ Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet. 2005;44(6):571-90.

  • 4. Findling RL. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: A review. Clin Ther. 2008;30(5):942-57.

  • 5. Yu G Li G-F Markowitz JS. Atomoxetine: A review of its pharmacokinetics and pharmacogenomics relative to drug disposition. J Child Adolesc Psychopharmacol. 2016;26(x):1-13.

  • 6. Ring BJ Gillespie JS Eckstein JA Wrighton SA. Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab Dispos. 2002;30(3):319-23.

  • 7. Simpson D Plosker GL. Spotlight on atomoxetine in adults with attentiondeficit hyperactivity disorder 1. 2004;18(6):397-401.

  • 8. Sauer JM Ponsler GD Mattiuz EL et al. Disposition and metabolic fate of atomoxetine hydrochloride: The role of CYP2D6 in human disposition and metabolism. Drug Metab Dispos. 2003;31(1):98-107.

  • 9. Matsui A Azuma J Witcher JW et al. Pharmacokinetics safety and tolerability of atomoxetine and effect of CYP2D6*10/*10 genotype in healthy Japanese men. J Clin Pharmacol. 2012;52(3):388-403.

  • 10. Cui YM Teng CH Pan AX et al. Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 allele. Br J Clin Pharmacol. Wiley-Blackwell; 2007;64(4):445-49.

  • 11. Sistonen J Sajantila A Lao O Corander J Barbujani G Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics. 2007;17(2):93-101.

  • 12. Zhou S-F. Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance. Clin Pharmacokinet. 2009;48(11):689-723.

  • 13. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5:6-13.

  • 14. Brown JT Bishop JR. Atomoxetine pharmacogenetics: associations with pharmacokinetics treatment response and tolerability. Pharmacogenomics. 2015;16(13):1513-20.

  • 15. LLerena A Naranjo MEG Rodrigues-Soares F Penas-LLedo EM Farinas H Tarazona-Santos E. Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations. Expert Opin Drug Metab Toxicol. 2014;10(11):1569-83.

  • 16. Zanger UM Raimundo S Eichelbaum M. Cytochrome P450 2D6: Overview and update on pharmacology genetics biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 2004;369(1):23-37.

  • 17. Gardiner SJ Begg EJ. Pharmacogenetics drug-metabolizing enzymes and clinical practice. Pharmacol Rev. 2006;58(3):521-90.

  • 18. Belle DJ Ernest CS Sauer J-M Smith BP Thomasson HR Witcher JW. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol. 2002;42(11):1219-27.

  • 19. Shah RR Smith RL. Addressing phenoconversion: The Achilles’ heel of personalized medicine. Br J Clin Pharmacol. 2015;79(2):222-40.

  • 20. Abraham BK Adithan C. Genetic Polymorphism of Cyp2D6. Indian J Pharmacol. 2001;33(2):147-69.

  • 21. Teh LK Bertilsson L. Pharmacogenomics of CYP2D6: molecular genetics interethnic differences and clinical importance. Drug Metab Pharmacokinet. 2012;27(1):55-67.

  • 22. Frank D Jaehde U Fuhr U. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol. 2007;63(4):321-33.

  • 23. Farid NA Bergstrom RF Ziege EA Parli CJ Lemberger L. Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects. J Clin Pharmacol. 1985;25(4):296-301.

  • 24. Wang B Yang L-P Zhang X-Z Huang S-Q Bartlam M Zhou S-F. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Drug Metab Rev. 2009;41(4):573-643.

  • 25. Pan X Jeong H. Estrogen-induced cholestasis leads to repressed CYP2D6 expression in CYP2D6-humanized mice. Mol Pharmacol. 2015;88(1):106-12.

  • 26. F Fijal BA Guo Y Li SG et al. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial. J Clin Pharmacol. 2015;55(10):1167-74.

  • 27. Michelson D Read H Ruff DD Witcher J Zhang S McCracken J. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry. 2007;46(2):242-51.

  • 28. Wanwimolruk S Prachayasittikul V Phopin K Prachayasittikul V. Cytochrome P450 enzyme mediated herbal drug interactions (Part 1). Excli J. 2014;13:347-91.

  • 29. Wanwimolruk S Phopin K Prachayasittikul V. Cytochrome P450 enzyme mediated herbal drug interactions (Part 2). Excli J. 2014;13:869-96.

Search
Journal information
Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 237 116 2
PDF Downloads 101 72 1